Mao, Huzhang
Eli Lilly (United States)
3 papers on CoChat
Most cited papers
- Verified
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 1,080
- Verified
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 792
- Verified
Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1).
Lee, C. J., Mao, H., Thieu, V. T., Landó, L. F., & Thomas, M. K. (2023) · Journal of the Endocrine Society
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 47
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free